[go: up one dir, main page]

MA37519B1 - Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 - Google Patents

Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1

Info

Publication number
MA37519B1
MA37519B1 MA37519A MA37519A MA37519B1 MA 37519 B1 MA37519 B1 MA 37519B1 MA 37519 A MA37519 A MA 37519A MA 37519 A MA37519 A MA 37519A MA 37519 B1 MA37519 B1 MA 37519B1
Authority
MA
Morocco
Prior art keywords
abl1
compounds
abl2
bcr
inhibiting
Prior art date
Application number
MA37519A
Other languages
English (en)
Other versions
MA37519A1 (fr
Inventor
Pascal Furet
Stephanie Kay Dodd
Robert Martin Grotzfeld
Wolfgang Jahnke
Darryl Brynley Jones
Paul Manley
Andreas Marzinzik
Xavier Francois Andre Pelle
Bahaa Salem
Joseph Schoepfer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37519A1 publication Critical patent/MA37519A1/fr
Publication of MA37519B1 publication Critical patent/MA37519B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des composés de formule (i) : dans laquelle y, y
MA37519A 2012-05-15 2013-05-09 Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 MA37519B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647174P 2012-05-15 2012-05-15
US201361790967P 2013-03-15 2013-03-15
PCT/IB2013/053768 WO2013171639A1 (fr) 2012-05-15 2013-05-09 Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1

Publications (2)

Publication Number Publication Date
MA37519A1 MA37519A1 (fr) 2016-06-30
MA37519B1 true MA37519B1 (fr) 2017-03-31

Family

ID=48670630

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37519A MA37519B1 (fr) 2012-05-15 2013-05-09 Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1

Country Status (50)

Country Link
US (2) US8829195B2 (fr)
EP (1) EP2861579B9 (fr)
JP (1) JP6078639B2 (fr)
KR (1) KR102091893B1 (fr)
CN (1) CN104302638B (fr)
AP (1) AP3613A (fr)
AR (1) AR091063A1 (fr)
AU (1) AU2013261127B2 (fr)
BR (1) BR112014026383B1 (fr)
CA (1) CA2868958C (fr)
CL (1) CL2014002757A1 (fr)
CO (1) CO7131380A2 (fr)
CR (1) CR20140519A (fr)
CU (1) CU24265B1 (fr)
CY (2) CY1120235T1 (fr)
DK (1) DK2861579T5 (fr)
DO (1) DOP2014000256A (fr)
EA (1) EA024391B1 (fr)
ES (1) ES2670601T3 (fr)
FR (1) FR22C1053I2 (fr)
GE (1) GEP201606532B (fr)
GT (1) GT201400253A (fr)
HR (1) HRP20180695T1 (fr)
HU (2) HUE039138T2 (fr)
IL (1) IL235566A (fr)
JO (1) JO3453B1 (fr)
LT (2) LT2861579T (fr)
LU (1) LUC00287I2 (fr)
MA (1) MA37519B1 (fr)
ME (1) ME03095B (fr)
MX (1) MX359014B (fr)
MY (1) MY169377A (fr)
NL (1) NL301201I2 (fr)
NO (1) NO2022043I1 (fr)
NZ (1) NZ701626A (fr)
PE (3) PE20150669A1 (fr)
PH (1) PH12014502531A1 (fr)
PL (1) PL2861579T3 (fr)
PT (1) PT2861579T (fr)
RS (1) RS57177B1 (fr)
SG (1) SG11201407152XA (fr)
SI (1) SI2861579T1 (fr)
SV (1) SV2014004850A (fr)
TN (1) TN2014000427A1 (fr)
TR (1) TR201807023T4 (fr)
TW (1) TWI560183B (fr)
UA (1) UA113208C2 (fr)
UY (1) UY34811A (fr)
WO (1) WO2013171639A1 (fr)
ZA (1) ZA201407065B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3632919T (lt) 2012-04-26 2023-02-27 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
EA201492007A1 (ru) * 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
CN104379574B (zh) * 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
BR112014027584B1 (pt) 2012-05-15 2023-01-24 Novartis Ag Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
SG11201407152XA (en) * 2012-05-15 2014-11-27 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (fr) 2013-01-14 2014-07-17 Incyte Corporation Composés de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
JPWO2015064764A1 (ja) * 2013-11-01 2017-03-09 宇部興産株式会社 アリーロイル（オキシ又はアミノ）ペンタフルオロスルファニルベンゼン化合物、薬学的に許容されるその塩、及びそのプロドラッグ
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015123352A1 (fr) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (fr) 2014-07-14 2016-01-21 Incyte Corporation Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
CN104478911A (zh) * 2014-12-19 2015-04-01 成都安斯利生物医药有限公司 一种制备3-三氟甲基吡咯硼酸的方法
WO2016100882A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Polythérapies
CN113181362B (zh) * 2015-01-13 2023-06-13 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
EP3964528A1 (fr) 2015-07-29 2022-03-09 Novartis AG Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
WO2017019896A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (fr) 2015-10-02 2017-04-06 Incyte Corporation Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
EP4424322A3 (fr) 2015-12-17 2025-04-16 Novartis AG Molécules d'anticorps anti-pd-1 et leurs utilisations
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
CN109790144A (zh) * 2016-04-29 2019-05-21 爱仕达生物技术有限责任公司 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
EP3519400A1 (fr) * 2016-09-27 2019-08-07 Novartis AG Systèmes tensioactifs pour la cristallisation de composés organiques
US20190240176A1 (en) * 2016-10-26 2019-08-08 The University Of Georgia Research Foundation, Inc. Methods of treatment for myeloid leukemia
RU2768887C2 (ru) * 2017-03-15 2022-03-25 Сан Фарма Эдвансд Рисёч Компани Лимитед Новая аморфная дисперсия (5-{ 5-[n'-(2-хлор-6-метилбензоил)гидразинокарбонил]-2-метил-фенилэтинил} -пиридин-2-ил)амида циклопропанкарбоновой кислоты
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JPWO2018216705A1 (ja) * 2017-05-23 2020-03-26 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
EP3642240A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3781156A4 (fr) * 2018-04-16 2022-05-18 C4 Therapeutics, Inc. Composés spirocycliques
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
KR102618168B1 (ko) * 2018-07-06 2023-12-27 일양약품주식회사 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물
US10889571B2 (en) 2018-09-18 2021-01-12 Terns, Inc. Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias
KR102119150B1 (ko) * 2018-10-23 2020-06-04 한국원자력의학원 N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
TW202444706A (zh) * 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
US11236070B2 (en) * 2019-05-16 2022-02-01 Novartis Ag Chemical process
GB201913110D0 (en) * 2019-09-11 2019-10-23 Benevolentai Bio Ltd New compounds and methods
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
WO2021143927A1 (fr) * 2020-01-19 2021-07-22 正大天晴药业集团股份有限公司 Composé agissant en tant qu'inhibiteur de bcr-abl
US20230097240A1 (en) * 2020-01-28 2023-03-30 Teva Pharmaceuticals International Gmbh Solid state forms of asciminib and processes for the preparation thereof
WO2021156360A1 (fr) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'interruption d'un traitement avec un inhibiteur de tyrosine kinase (tki)
CN111321200A (zh) * 2020-02-28 2020-06-23 广州安镝声生物医药科技有限公司 一种细胞外abl1激酶活性检测试剂盒及其应用
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2022206937A1 (fr) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline de chlorhydrate de composé nicotinamide à substitution par pyrazole et son procédé de préparation
KR20240006600A (ko) 2021-05-11 2024-01-15 노파르티스 아게 투약 요법
CA3219641A1 (fr) * 2021-05-28 2022-12-01 Yinsheng ZHANG Compose utilise comme inhibiteur de bcr-abl
CN114149409B (zh) * 2021-11-16 2024-03-22 中国药科大学 一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物
CN116135851B (zh) * 2021-11-17 2025-09-23 武汉众诚康健生物医药科技有限公司 一种芳香胺化合物及其应用
WO2023114759A2 (fr) * 2021-12-13 2023-06-22 The Regents Of The University Of California Inhibiteurs d'abl et leurs utilisations
CN115109048B (zh) * 2022-08-10 2023-12-08 中国药科大学 一种(杂)芳基酰胺类化合物
WO2024100212A1 (fr) 2022-11-10 2024-05-16 Synthon B.V. Forme cristalline du chlorhydrate d'asciminib
WO2024257116A1 (fr) * 2023-06-13 2024-12-19 Natco Pharma Limited Nouvelles formes polymorphes d'asciminib et leurs sels pharmaceutiques
WO2025146653A1 (fr) * 2024-01-04 2025-07-10 Biophore India Pharmaceuticals Pvt. Ltd Procédé de préparation de n-[4(chlorodifluorométhoxy)phényl]-6-[(3r)-3-hydroxy pyrrolidin-l-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide et ses sels pharmaceutiquement acceptables
WO2025151311A1 (fr) * 2024-01-10 2025-07-17 Board Of Regents, The University Of Texas System Dérivés de nicotinamide

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2845997A1 (de) 1978-10-23 1980-04-30 Bayer Ag Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5017211A (en) 1987-09-23 1991-05-21 Ciba-Geigy Corporation Heterocyclic compounds
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
ATE247724T1 (de) 1996-09-06 2003-09-15 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (fr) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, de leurs intermediaires et de leurs analogues
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
CA2397493A1 (fr) 2000-01-27 2001-08-02 Cytovia, Inc. Nicotinamides substituees, leurs analogues, activateurs des caspases et inducteurs de l'apoptose et leur emploi
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2003039529A1 (fr) 2001-11-07 2003-05-15 4Sc A.G. Agents antibacteriens selectifs
WO2003055477A1 (fr) 2001-12-21 2003-07-10 7Tm Pharma A/S Methode de traitement de troubles lies au recepteur de la melanocortine (mc), faisant intervenir un chelate et/ou un chelateur
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ES2571779T3 (es) 2002-12-13 2016-05-26 Ym Biosciences Australia Pty Inhibidores de cinasa a base de nicotinamida
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20080167347A1 (en) 2005-01-20 2008-07-10 Shiongi & Co., Ltd. Ctgf Expression Inhibitor
WO2006120178A1 (fr) 2005-05-11 2006-11-16 Novo Nordisk A/S Nouveaux composes d'haloalkylsulfone substitues utiles dans le traitement de l'obesite et de diabetes
WO2007002441A1 (fr) 2005-06-24 2007-01-04 Emory University Procedes d'utilisation d'inhibiteurs de tyrosine kinase competitive non atp afin de traiter des infections pathogenes
PL1746097T3 (pl) 2005-07-20 2010-06-30 Aventis Pharma Sa Skondensowane heterocykle 1,4-dihydropirydynowe, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje
CA2644143C (fr) * 2006-04-05 2013-10-01 Novartis Ag Combinaisosns comprenant des inhibiteurs de bcr-abl/c-kit/pdgf-r tk pour le traitement du cancer
WO2008021725A2 (fr) 2006-08-11 2008-02-21 Smithkline Beecham Corporation Composés chimiques
CN101528744A (zh) 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
US7939690B2 (en) * 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
CN101627027B (zh) * 2007-01-05 2013-06-19 百时美施贵宝公司 氨基吡唑激酶抑制剂
WO2008112695A2 (fr) 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
WO2008124393A1 (fr) 2007-04-04 2008-10-16 Irm Llc Derives de benzothiazole et leur utilisation en tant qu'inhibiteurs des proteines kinases
WO2008144253A1 (fr) 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
BRPI0815038A2 (pt) 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
CN101801935B (zh) 2007-09-17 2014-12-03 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CA2726158A1 (fr) 2008-06-11 2009-12-17 Dana Farber Cancer Institute Composes et compositions utiles pour le traitement de la malaria
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
CN102548987B (zh) 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 作为激酶抑制剂的氟取代化合物及其使用方法
JP2011057661A (ja) 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
SG10201407453TA (en) 2009-11-13 2014-12-30 Genosco Kinase inhibitors
JO3634B1 (ar) * 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
US8999973B2 (en) 2010-01-29 2015-04-07 Hanmi Science Co., Ltd Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
ES2634716T3 (es) 2011-05-31 2017-09-28 Celgene International Ii Sàrl Nuevos estabilizantes y moduladores del receptor GLP-1
BR112014027584B1 (pt) 2012-05-15 2023-01-24 Novartis Ag Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
EA201492007A1 (ru) 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
SG11201407152XA (en) 2012-05-15 2014-11-27 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CN104379574B (zh) * 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物

Also Published As

Publication number Publication date
AP2014007992A0 (en) 2014-10-31
TW201400471A (zh) 2014-01-01
DK2861579T3 (en) 2018-05-28
LTC2861579I2 (fr) 2024-08-26
HK1203495A1 (en) 2015-10-30
DK2861579T5 (da) 2022-10-24
AP3613A (en) 2016-02-29
CL2014002757A1 (es) 2015-01-23
MY169377A (en) 2019-03-26
CR20140519A (es) 2015-03-26
UY34811A (es) 2013-12-31
PE20150669A1 (es) 2015-05-17
NZ701626A (en) 2016-02-26
GT201400253A (es) 2017-09-28
FR22C1053I1 (fr) 2022-12-16
US20140343086A1 (en) 2014-11-20
RS57177B1 (sr) 2018-07-31
CY1120235T1 (el) 2019-07-10
EP2861579B1 (fr) 2018-02-21
TN2014000427A1 (en) 2016-03-30
UA113208C2 (xx) 2016-12-26
CN104302638A (zh) 2015-01-21
EP2861579A1 (fr) 2015-04-22
PL2861579T3 (pl) 2018-07-31
ES2670601T3 (es) 2018-05-31
CU24265B1 (es) 2017-07-04
US8829195B2 (en) 2014-09-09
SG11201407152XA (en) 2014-11-27
NL301201I2 (nl) 2022-12-07
CU20140131A7 (es) 2015-04-29
AU2013261127A1 (en) 2014-11-20
LT2861579T (lt) 2018-05-10
CY2022033I2 (el) 2023-01-05
EP2861579B9 (fr) 2018-08-29
DOP2014000256A (es) 2015-02-27
ES2670601T9 (es) 2022-11-30
ZA201407065B (en) 2016-08-31
HUS2200046I1 (hu) 2022-11-28
TWI560183B (en) 2016-12-01
JP2015521185A (ja) 2015-07-27
PE20161416A1 (es) 2017-01-08
LTPA2022523I1 (fr) 2022-12-12
SV2014004850A (es) 2018-04-04
BR112014026383B1 (pt) 2020-11-17
CN104302638B (zh) 2016-08-24
PH12014502531B1 (en) 2015-01-12
NO2022043I1 (en) 2022-10-25
PE20210667A1 (es) 2021-04-05
JP6078639B2 (ja) 2017-02-08
CO7131380A2 (es) 2014-12-01
HUE039138T2 (hu) 2018-12-28
IL235566A (en) 2016-09-29
JO3453B1 (ar) 2020-07-05
CA2868958A1 (fr) 2013-11-21
CY2022033I1 (el) 2023-01-05
WO2013171639A1 (fr) 2013-11-21
US20130310395A1 (en) 2013-11-21
HRP20180695T1 (hr) 2018-06-01
ME03095B (fr) 2019-01-20
KR102091893B1 (ko) 2020-03-23
LUC00287I2 (fr) 2025-05-12
EA024391B1 (ru) 2016-09-30
TR201807023T4 (tr) 2018-06-21
AR091063A1 (es) 2014-12-30
KR20150020170A (ko) 2015-02-25
AU2013261127B2 (en) 2015-03-12
MX2014013374A (es) 2015-01-16
SI2861579T1 (en) 2018-05-31
EA201491824A1 (ru) 2015-02-27
MA37519A1 (fr) 2016-06-30
PH12014502531A1 (en) 2015-01-12
PT2861579T (pt) 2018-04-27
GEP201606532B (en) 2016-08-25
IL235566A0 (en) 2015-02-01
FR22C1053I2 (fr) 2023-11-10
BR112014026383A2 (pt) 2017-06-27
CA2868958C (fr) 2020-09-01
MX359014B (es) 2018-09-12

Similar Documents

Publication Publication Date Title
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA35086B1 (fr) Compose de triazolopyridine
MA35357B1 (fr) Composes de type anilines
MA35819B1 (fr) Composés hétéroaryl pyridones et aza-pyridones en tant qu'inhibiteurs de l'activité btk
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA33492B1 (fr) Inhibiteurs de bace
HRP20090235B1 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d
NZ716420A (en) Fused heterocyclic compounds as sodium channel modulators
MA35049B1 (fr) Triazolopyridines
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
PH12013502516A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MA37990B1 (fr) Benzamides
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
IN2014DN07082A (fr)
EP2806876A4 (fr) Composés renforçant l'activité des protéasomes
MA34578B1 (fr) Composés de tétrahydrofuranyl disubstitués en tant qu'antagonistes du récepteur de la bradykinine b1
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA20150280A2 (fr) Dérivés d'aryléthynyle